Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.66 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.66 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.66 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.66 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.66 |
| ▸ | CCR3 | P51677 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1373308 | 0.98 | GRIN2D (0.64) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL5233388 | 0.91 | MEN1 (0.61) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL19382678 | 0.91 | GRIN2D (0.56) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL8485320 | 0.91 | GRIN2D (0.56) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL15857848 | 0.87 | GRIN1 (0.63) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL4281407 | 0.87 | GAA (0.64) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| Lithium Ion SCHEMBL25243064 | 0.86 | GRIN2D (0.61) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL5206098 | 0.86 | OPRM1 (0.56) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL5999857 | 0.86 | MEN1 (0.64) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A | |
| SCHEMBL6001210 | 0.84 | MEN1 (0.53) | GRIN2BGRIN2DGRIN3BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | COUNCIL SCIENT IND RES (IN) | 2026-03-19 | — | — | US | disclosed |
| EP-4551241-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| EP-1513811-B1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARM GMBH (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-1565453-A4 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL|BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7244743-B2 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1565453-A1 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1513811-A1 | NON-PEPTIDIC BRS-3 AGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004048364-A1 | 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003104196-A1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | CNR1, CNR2, CBR1 | GRIN2B 799/4885GRIN2D 1187/4885GRIN3B 1589/4885 |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GRIN2B 1/4885GRIN2D 7/4885GRIN3B 4/4885 |
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | HTR5A, HTR2C, TPH1 | GRIN2B 149/4885GRIN2D 82/4885GRIN3B 154/4885 |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | BRS3, NPR3, ADRB3 | GRIN2B 325/4885GRIN2D 774/4885GRIN3B 160/4885 |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | GRIN2B 5/4885GRIN2D 9/4885GRIN3B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.